The Oncotype DX Breast Recurrence Score® test provides significant value in clinical practice
Loading component...
Node-Positive
Choose your location and language
Choose your country:
- Order tests, track orders, get results, and more.
Clinical evidence has demonstrated:
The SWOG-8814 study established the Oncotype DX test as predictive of CT benefit in node-positive postmenopausal patients.
Another recent study published in 2023 shows that the Oncotype DX test increases confidence and concordance among oncologists in adjuvant chemotherapy recommendations for early-stage breast cancer.
The study concludes that:
In summary, adjuvant chemotherapy may be guided with the Oncotype DX test to identify a significant proportion of node-positive patients (with up to 3 positive nodes) who may not benefit from the addition of chemotherapy.
The Oncotype DX Breast Recurrence Score test should be used for:
Adjuvant chemotherapy may be guided with the Oncotype DX Breast Recurrence Score test to identify:
Since clinical risk features alone are not sufficient to determine CT benefit, the Oncotype DX Breast Recurrence Score test should be used for:
National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. ASCO and ESMO are trademarks of the American Society of Clinical Oncology and European Society for Medical Oncology.
NCCN, National Institute for Health and Care Excellence (NICE), St Gallen International Consensus Panel, ASCO and ESMO do not endorse any product or therapy.
NICE DG34 2018 Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Available at